Researchers to examine thrombolysis for treatment of DVT in leg

NewsGuard 100/100 Score

Blood clots in the leg (deep vein thrombosis - DVT) occur commonly. In one-half of the cases, the blood clot will break loose and travel through the bloodstream to the lungs - which may be life-threatening. Current treatment stops the blood clot from moving, but does not prevent permanent damage to the vein. Many patients may suffer long-term swelling and pain in their legs.

Today, patients are normally treated with the blood-thinning medication warfarin and must wear support hose for two years. A project led by Dr Per Morten Sandset, a professor at Oslo University Hospital, and funded under the Research Programme on Clinical Research (KLINISKFORSKNING) at the Research Council will examine whether patients will benefit from additional treatment with drugs that dissolve blood clots (a treatment called thrombolysis).

May be of international significance

Preliminary findings after the first six months of the clinical trial show that the veins tend to remain open more often among patients who receive thrombolysis in addition to conventional treatment. This indicates that the vein is functioning as it should and is draining blood from the leg. The researchers will follow up patients for five years to chart the long-term effects of the treatment.

"If we succeed in demonstrating that patients experience fewer chronic conditions or discomfort - and few side effects - it will be a major breakthrough. We can then recommend that thrombolysis be put into use internationally for treatment of DVT in the leg," asserts Dr Sandset.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis